GB1592496A - Method of producing vaccine for the immunotherapy of neoplastic disease - Google Patents
Method of producing vaccine for the immunotherapy of neoplastic disease Download PDFInfo
- Publication number
- GB1592496A GB1592496A GB48910/77A GB4891077A GB1592496A GB 1592496 A GB1592496 A GB 1592496A GB 48910/77 A GB48910/77 A GB 48910/77A GB 4891077 A GB4891077 A GB 4891077A GB 1592496 A GB1592496 A GB 1592496A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer
- cells
- vaccine
- manganous
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 23
- 238000009169 immunotherapy Methods 0.000 title claims description 19
- 201000010099 disease Diseases 0.000 title claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 13
- 230000001613 neoplastic effect Effects 0.000 title claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 142
- 210000004027 cell Anatomy 0.000 claims description 128
- 201000011510 cancer Diseases 0.000 claims description 122
- 239000000427 antigen Substances 0.000 claims description 86
- 108091007433 antigens Proteins 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229920002307 Dextran Polymers 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 8
- -1 fatty acid salt Chemical class 0.000 claims description 8
- 210000003850 cellular structure Anatomy 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 3
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 239000011565 manganese chloride Substances 0.000 claims description 3
- 235000002867 manganese chloride Nutrition 0.000 claims description 3
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 2
- IPJKJLXEVHOKSE-UHFFFAOYSA-L manganese dihydroxide Chemical compound [OH-].[OH-].[Mn+2] IPJKJLXEVHOKSE-UHFFFAOYSA-L 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000028993 immune response Effects 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 18
- 230000001900 immune effect Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 230000001413 cellular effect Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 239000011572 manganese Substances 0.000 description 10
- 229910052748 manganese Inorganic materials 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 229940093474 manganese carbonate Drugs 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SZINCDDYCOIOJQ-UHFFFAOYSA-L manganese(2+);octadecanoate Chemical compound [Mn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O SZINCDDYCOIOJQ-UHFFFAOYSA-L 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- PMQJYWORJJEMQC-UHFFFAOYSA-N manganese;dihydrate Chemical compound O.O.[Mn] PMQJYWORJJEMQC-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74460176A | 1976-11-24 | 1976-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1592496A true GB1592496A (en) | 1981-07-08 |
Family
ID=24993313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB48910/77A Expired GB1592496A (en) | 1976-11-24 | 1977-11-24 | Method of producing vaccine for the immunotherapy of neoplastic disease |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU511417B2 (da) |
| GB (1) | GB1592496A (da) |
| IE (1) | IE45993B1 (da) |
| IN (1) | IN146800B (da) |
| MX (1) | MX4306E (da) |
| NZ (1) | NZ185768A (da) |
| ZA (1) | ZA776822B (da) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2144330A (en) * | 1983-08-04 | 1985-03-06 | Nat Res Dev | Immunological compositions |
| EP0173951A2 (de) * | 1984-09-06 | 1986-03-12 | BEHRINGWERKE Aktiengesellschaft | Tumortherapeutikum und Verfahren zu seiner Herstellung |
-
1977
- 1977-11-15 ZA ZA00776822A patent/ZA776822B/xx unknown
- 1977-11-17 IN IN396/DEL/77A patent/IN146800B/en unknown
- 1977-11-22 AU AU30822/77A patent/AU511417B2/en not_active Expired
- 1977-11-23 NZ NZ185768A patent/NZ185768A/xx unknown
- 1977-11-23 IE IE2371/77A patent/IE45993B1/en not_active IP Right Cessation
- 1977-11-23 MX MX776575U patent/MX4306E/es unknown
- 1977-11-24 GB GB48910/77A patent/GB1592496A/en not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2144330A (en) * | 1983-08-04 | 1985-03-06 | Nat Res Dev | Immunological compositions |
| US4661346A (en) * | 1983-08-04 | 1987-04-28 | National Research Development Corporation | Immunological compositions including a peptide and osmium or ruthenium tetroxide |
| EP0173951A2 (de) * | 1984-09-06 | 1986-03-12 | BEHRINGWERKE Aktiengesellschaft | Tumortherapeutikum und Verfahren zu seiner Herstellung |
| EP0173951A3 (en) * | 1984-09-06 | 1988-06-08 | Behringwerke Aktiengesellschaft | Tumour therapeutic agent and process for its preparationtumour therapeutic agent and process for its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ185768A (en) | 1979-10-25 |
| MX4306E (es) | 1982-03-19 |
| AU3082277A (en) | 1979-05-31 |
| IE45993L (en) | 1978-05-24 |
| IE45993B1 (en) | 1983-01-26 |
| AU511417B2 (en) | 1980-08-21 |
| IN146800B (da) | 1979-09-15 |
| ZA776822B (en) | 1979-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4720386A (en) | Vaccine and method for immunotherapy of neoplastic disease | |
| Boros et al. | Delayed hypersensitivity-type granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from Schistosoma mansoni eggs | |
| Nicholson-Weller et al. | Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b, 2a. | |
| Molinari et al. | Taenia solium: immunity in hogs to the cysticercus | |
| Whyte et al. | Protection of rainbow trout, Oncorhynchus mykiss (Richardson), against Diplostomum spathaceum (Digenea): the role of specific antibody and activated macrophages | |
| Mahmoud et al. | In vitro killing of schistosomula of Schistosoma mansoni by BCG and C. parvum-activated macrophages | |
| WO1997011667A2 (en) | Therapeutic applications using horse serum | |
| Schriber et al. | Induction of blood eosinophilia by pulmonary embolization of antigen-coated particles: the relationship to cell-mediated immunity | |
| Youdim et al. | Thymus dependency of cells involved in transfer of delayed hypersensitivity to Listeria monocytogenes in mice | |
| Rickard | Hypothesis for the long term survival of Taenia pisiformis cysticerci in rabbits | |
| Hildemann et al. | Relationship between skin transplantation immunity and the formation of humoral isoantibodies in mice | |
| MARSH et al. | Immunologic aspects of osteosarcoma and their application to therapy: a preliminary report | |
| GB1592496A (en) | Method of producing vaccine for the immunotherapy of neoplastic disease | |
| IE47736B1 (en) | Improvements in or relating to a method of producing a vaccine for use in the immunotherapy of neoplastic disease | |
| Hanna Jr et al. | Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs | |
| Sonozaki et al. | The macrophage disappearance reaction: II. Mediation by lymphocytes which lack complement receptors | |
| US4001080A (en) | Production of immunological materials | |
| Minden et al. | Protection against guinea pig hepatomas by pretreatment with subcelluar fractions of Mycobacterium bovis (BCG) | |
| CA1102696A (en) | Vaccine and method for immunotherapy of neoplastic disease | |
| Papermaster et al. | Desensitization: II. Passive transfer of the desensitized state by serum from desensitized animals | |
| Shupe et al. | Stimulated chemotactic response in neutrophils from Trichinella pseudospiralis-infected mice and the neutrophilotactic potential of Trichinella extracts | |
| Shear et al. | Properties of the accelerant factor (s) for a transplantable mouse mammary tumor, Z8352 | |
| Rosenfeld et al. | Transfer factor: a subcellular component that transmits information for specific immune responses | |
| Southam | Are there host defenses against cancer? | |
| Anacker et al. | Conversion of the phase I antigen of Coxiella burnetii to hapten by phenol treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19941124 |